Global Pancreatic Cancer Therapeutics Market 2019-2023

Global Pancreatic Cancer Therapeutics Market 2019-2023

About this market

Availability of improved diagnostic modalities to drive growth in the market. To combat the shortcomings in the prognosis of pancreatic cancer, advanced diagnostic aids based on the principles of complementary DNA (cDNA) fingerprinting, PCR, and DNA microarray, and molecular profiling are being developed. Technavio’s analysts have predicted that the pancreatic cancer therapeutics market will register a CAGR of more than 8% by 2023.

Market Overview

Robust pipeline and new drug approvals

The pipeline for the treatment of pancreatic cancer includes novel therapeutic approaches, including vaccines, gene therapy, stem cell therapy, and targeted therapy products.

High cost of treatments

Pancreatic cancer requires long term treatment, which increases the treatment cost and the economic burden on patients.

For the detailed list of factors that will drive and challenge the growth of the pancreatic cancer therapeutics market during the 2019-2023, view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Pfizer and Shire the competitive environment is quite intense. Factors such as the robust pipeline and new drug approvals and the availability of improved diagnostic modalities, will provide considerable growth opportunities to pancreatic cancer therapeutics manufactures. Eli Lilly, F. Hoffmann-La Roche, Novartis, Pfizer, and Shire are some of the major companies covered in this report.


PRESS RELEASE

Technavio Announces the Publication of its Research Report – Global Pancreatic Cancer Therapeutics Market 2019-2023

Commenting on the report, an analyst from Technavio’s team said: “The latest trend gaining momentum in the market is the availability of improved diagnostic modalities.”

According to the report, one of the major drivers for this market is the robust pipeline and new drug approvals.

Further, the report states that one of the major factors hindering the growth of this market is the high cost of treatments.

Companies Mentioned

Eli Lilly
F. Hoffmann-La Roche
Novartis
Pfizer
Shire

  • Executive summary
  • Scope of the report
    • Preface
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global oncology therapeutics market
      • Table Segments of global oncology therapeutics market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Pipeline analysis
    • Table Therapies in late stage development for pancreatic cancer
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • Targeted therapy - Market size and forecast 2018-2023
      • Table Targeted therapy - Market size and forecast 2018-2023 ($ millions)
      • Table Targeted therapy - Year-over-year growth 2019-2023 (%)
    • Chemotherapy - Market size and forecast 2018-2023
      • Table Chemotherapy - Market size and forecast 2018-2023 ($ millions)
      • Table Chemotherapy - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Market segmentation by type
    • Exocrine pancreatic cancer
    • Endocrine pancreatic cancer
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • Americas - Market size and forecast 2018-2023
      • Table Americas - Market size and forecast 2018-2023 ($ millions)
      • Table Americas - Year-over-year growth 2019-2023 (%)
    • EMEA - Market size and forecast 2018-2023
      • Table EMEA - Market size and forecast 2018-2023 ($ millions)
      • Table EMEA - Year-over-year growth 2019-2023 (%)
    • APAC - Market size and forecast 2018-2023
      • Table APAC - Market size and forecast 2018-2023 ($ millions)
      • Table APAC - Year-over-year growth 2019-2023 (%)
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table New drug approvals for pancreatic cancer
    • Market challenges
      • Table Patent expiration dates for therapies for pancreatic cancer
      • Table Impact of drivers and challenges
  • Market trends
    • Table Immunotherapy products under research
    • Table Combination therapies for pancreatic cancer
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • Eli Lilly
      • Table Eli Lilly - Vendor overview
      • Table Eli Lilly - Business segments
      • Table Eli Lilly - Organizational developments
      • Table Eli Lilly - Geographic focus
      • Table Eli Lilly - Segment focus
      • Table Eli Lilly - Key offerings
    • F. Hoffmann-La Roche
      • Table F. Hoffmann-La Roche - Vendor overview
      • Table F. Hoffmann-La Roche - Business segments
      • Table F. Hoffmann-La Roche - Organizational developments
      • Table F. Hoffmann-La Roche - Geographic focus
      • Table F. Hoffmann-La Roche - Segment focus
      • Table F. Hoffmann-La Roche - Key offerings
    • Novartis
      • Table Novartis - Vendor overview
      • Table Novartis - Business segments
      • Table Novartis - Organizational developments
      • Table Novartis - Geographic focus
      • Table Novartis - Segment focus
      • Table Novartis - Key offerings
    • Pfizer
      • Table Pfizer - Vendor overview
      • Table Pfizer - Business segments
      • Table Pfizer - Organizational developments
      • Table Pfizer - Geographic focus
      • Table Pfizer - Segment focus
      • Table Pfizer - Key offerings
    • Shire
      • Table Shire - Vendor overview
      • Table Shire - Business segments
      • Table Shire - Organizational developments
      • Table Shire - Geographic focus
      • Table Shire - Key offerings
  • Appendix
    • Research methodology
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook